News

News Subscription

Apr 07. 2014
Basilea's oncology drug candidate BAL101553 demonstrates broad antitumor activity in treatment-resistant breast cancer models as presented at AACR
Read more
Download
Feb 28. 2014
Basilea swaps its isavuconazole North American co-promote rights for full isavuconazole rights outside of North America
Read more
Download
Feb 27. 2014
Basilea reports that isavuconazole receives Qualified Infectious Disease Product designation from U.S. FDA for the treatment of invasive mucormycosis
Read more
Download
Feb 11. 2014
Basilea 2013 full-year results: strong operational and financial performance
Read more
Download
Dec 03. 2013
Basilea reports that isavuconazole receives Qualified Infectious Disease Product (QIDP) designation from U.S. FDA for the treatment of invasive aspergillosis
Read more
Download
Nov 18. 2013
Basilea reports isavuconazole orphan drug designation for treatment of zygomycosis by U.S. FDA
Read more
Download
Nov 04. 2013
Basilea appoints new Chief Financial Officer
Read more
Download
Oct 23. 2013
Basilea's antibiotic ceftobiprole obtains regulatory approval in Europe for pneumonia
Read more
Download
Sep 30. 2013
Basilea reports positive topline phase 3 results for antifungal isavuconazole
Read more
Download
Sep 16. 2013
Swissmedic accepts for review Basilea's ceftobiprole Marketing Authorization Application for the treatment of pneumonia
Read more
Download